SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
bligations may continue. See	
nstruction 1(b)	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response

			••••••••••••••••••••••••••••••••••••••						
1. Name and Address of Reporting Person* LAWLOR AUGUSTINE			2. Issuer Name and Ticker or Trading Symbol <u>LEAP THERAPEUTICS, INC.</u> [LPTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
					Director	Х	10% Owner		
(Last)	Last) (First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year)	x	Officer (give title below)		Other (specify below)		
	RAPEUTICS, INC	()	06/11/2019		Chief Operating Officer				
47 THORNDIK	E STREET SUITE	B1-1							
			4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check						
(Street)				Line)					
CAMBRIDGE	MA	02141			Form filed by One I	Report	ing Person		
P					Form filed by More	than C	One Reporting		
(City)	(State)	(Zip)			Person				
	٦	able I - Non-Deriv	ative Securities Acquired, Disposed of, or Benefic	cially C	Dwned				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (4. Securities A Disposed Of (Securities	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Employee Stock Option (Right to Buy)	\$1.39	06/11/2019		A		200,000		(1)	06/10/2029	Common Stock	200,000	\$0	200,000	D	

Explanation of Responses:

1. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of June 11, 2019, the Vesting Start Date.

/s/ Douglas E. Onsi as attorney-06/12/2019 in-fact for Augustine Lawlor

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date